IN AUSTRALIA, NOVATEARS® EYE DROPS ARE AVAILABLE ON
THE PHARMACEUTICAL BENEFITS SCHEME (PBS) FROM NOW ON
Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, is the manufacturer of NovaTears®, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD).